דילוג לתוכן הראשי
xMedica

NCT07636590ClinicalTrials.gov

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

A Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

תצפיתידרושים 500 משתתפים21 אתריםמדינה אחת

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 18 days after the recorded start)First posted 2026-06-09; recorded start 2026-05-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Claris Biotherapeutics, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 500 participants (target), run at 21 sites.

How this score is built
  • Enrolment26/40

    500 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale1/10

    Claris Biotherapeutics, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

מצבים רפואיים

  • Limbal Stem Cell Deficiency

זכאות

זכאות
מיןהכול
גילאים12 Years – 99 Years
מתנדבים בריאיםלא
שיטת דגימהPROBABILITY_SAMPLE

אוכלוסיית המחקר

Adult and adolescent subjects with qualifying LSCD

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit * Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1 * Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1 * Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted. Exclusion Criteria: * Any active ocular infection in either eye at either the Screening or Day 1 visits * Active sterile iritis or uveitis in either eye at Screening or Day 1 visits * Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s) Note: Other inclusion/exclusion criteria apply.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרתצפיתי
שלבלא צוין ברשומת המרשם
הקצאהלא צוין ברשומת המרשם
מודל ההתערבותלא צוין ברשומת המרשם
מטרה ראשיתלא צוין ברשומת המרשם
הסתרהלא צוין ברשומת המרשם
גיוסדרושים 500 משתתפים

נותן חסות ושותפים

  • Claris Biotherapeutics, Inc. נותן חסות

זרועות והתערבויות

  • Non-interventional

    No product administration.

התערבויות

  • אחר Non-interventional

    Non-interventional

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    מסגרת זמן Screening through Week 84

  2. מדד תוצאה ראשוני

    Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    מסגרת זמן Screening through Week 84

  3. מדד תוצאה ראשוני

    Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    מסגרת זמן Screening through Week 84

  4. מדד תוצאה ראשוני

    Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    מסגרת זמן Screening through Week 84

  5. מדד תוצאה ראשוני

    Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    מסגרת זמן Screening through Week 84

  6. מדד תוצאה ראשוני

    Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    מסגרת זמן Screening through Week 84

  7. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    מסגרת זמן Screening through Week 84

  8. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    מסגרת זמן Screening through Week 84

  9. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    מסגרת זמן Screening through Week 84

  10. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    מסגרת זמן Screening through Week 84

  11. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    מסגרת זמן Screening through Week 84

  12. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    מסגרת זמן Screening through Week 84

  13. מדד תוצאה משני

    Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    מסגרת זמן Screening through Week 84

תאריכים

תאריכים
תאריך התחלה22 במאי 2026 (בפועל)
סיום ראשוני1 במרץ 2028 (משוער)
סיום1 במרץ 2028 (משוער)
פורסם לראשונה9 ביוני 2026 (בפועל)
עודכן לאחרונה18 בנובמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהנובמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

21 אתרים מגייסים

United States

United States
מתקןעירמדינה או אזורמצב
Claris Investigative SiteCarmelIndianaמגייס
Claris Investigative SiteCranberry TownshipPennsylvaniaמגייס
Claris Investigative SiteDraperUtahמגייס
Claris Investigative SiteHuntington BeachCaliforniaמגייס
Claris Investigative SiteIndianapolisIndianaמגייס
Claris Investigative SiteKansas CityMissouriמגייס
Claris Investigative SiteLa JollaCaliforniaמגייס
Claris Investigative SiteLos AngelesCaliforniaמגייס
Claris Investigative SiteLouisvilleKentuckyמגייס
Claris Investigative SiteMinnetonkaMinnesotaמגייס
Claris Investigative SiteNorfolkVirginiaמגייס
Claris Investigative SiteOverland ParkKansasמגייס
Claris Investigative SitePalisades ParkNew Jerseyמגייס
Claris Investigative SitePortlandOregonמגייס
Claris Investigative SiteRockville CentreNew Yorkמגייס
Claris Investigative SiteSan AntonioTexasמגייס
Claris Investigative SiteSioux FallsSouth Dakotaמגייס
Claris Investigative SiteSmyrnaTennesseeמגייס
Claris Investigative SiteSouth DartmouthMassachusettsמגייס
Claris Investigative SiteTampaFloridaמגייס
Claris Investigative SiteWichitaKansasמגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 18 בנובמבר 2026

    אתר נוסף

    13 sites added (21 total)

    821

  2. 6 באוגוסט 2026

    אתר נוסף

    6 sites added (8 total)

    28